… compared with erlotinib for advanced non-small-cell lung … Although our findings suggest that
efficacy might not differ between … with non-small-cell lung cancer as second-line or third-line …

… The efficacy and safety results of this study have been … - or third-line erlotinib versus BSC,
patients receiving erlotinib had a … that erlotinib significantly improves QoL when compared with …

… about enhanced toxicity or decreased efficacy. Secondline … Phase III study comparing
oral topotecan to intravenous … trial of erlotinib in advanced non-small cell lung cancer. J Natl …

… receptor (EGFR) inhibitors erlotinib, gefitinib, and cetuximab, … seems to compare favorably
to that reported in previous … Although interpretation of the efficacy results of the present study is …

… as a second- or third-line single agent of molecular targeted therapy in patients with …
result when vandetanib versus gefitinib was used in patients with advanced non-small cell …

… -line treatment in 1 patient, as third-line treatment in 12 … treatment periods with gefitinib, but
there were differences … mutation status is not related to the efficacy of erlotinib after gefitinib …

… -line and third-line for both erlotinib and gefitinib is in the … The promising efficacy of erlotinib
monotherapy in this study … Erlotinib plus gemcitabine compared to gemcitabine alone in …

… information on the efficacy of third-line erlotinib versus BSC … the comparison of chemotherapy
versus BSC in the third-line … to DCT and gefitinib as third-line treatment. The forest plot …

… The results show no significant difference in efficacy between … 8], as is the case for gefitinib
[21] and erlotinib [22]. Moreover, … trial of erlotinib in patients with advanced non-small cell lung …

… on efficacy and toxicity between mono-therapy and doublets … survival benefit from gefitinib
and erlotinib. The second-line … comparison of different drugs efficacy in the third-line therapy, …